Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Ribavirin + PEG-IFN alfa-2b in Low Weight HCV Genotype 1
NCT00686777Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2008
- Primary completion
- Dec 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 4 trial of ribavirin in hepatitis C (HCV), sponsored by Merck & Co.. Started Jan 2008; status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00686777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686777.